Maxor Completes Its Acquisition of Pharmaceutical Specialties, Inc. (PSI)
AMARILLO, Texas, Dec. 2, 2016 /PRNewswire/ — Maxor National Pharmacy Services, LLC (“Maxor”), today announced that it has completed its acquisition of Pharmaceutical Specialties, Inc. (“PSI”). The combination of Texas-based Maxor Specialty / IV Solutions and Georgia-based PSI bring together both company’s clinical expertise and high-touch patient service models to provide patients, physicians, manufacturers, and payers an industry-leading specialty pharmacy.
Established in 1926, Maxor is a leading pharmacy services platform that consists of three primary business segments: (i) Maxor Specialty and IV Solutions, providing specialty pharmacy, respiratory, and home infusion services; accredited by the Accreditation Commission for Health Care and by The Joint Commission, respectively; (ii) MaxorPlus, providing client and patient-focused URAC accredited pharmacy benefit management (PBM) services with desired clinical outcomes; and (iii) Maxor Pharmacy Management and Consulting Services, providing on-site outpatient pharmacy management, 340B audits, and consulting services to hospitals, health systems, Federally Qualified Health Plans, DSH hospitals, and self-funded employer groups.
These segments offer complementary services that aim to improve the health of patients and efficiently manage pharmacy expenditures for Maxor’s patients and clients. More information on Maxor can be found by visiting www.maxor.com.
Pharmaceutical Specialties, Inc. is a leading pharmacy specializing in pulmonary medicine including cystic fibrosis and bronchiectasis, endocrine therapies including growth hormone, and GI medicine including Hepatitis C and Crohn’s disease.
SOURCE Maxor National Pharmacy Services, LLC